Bisphosphonates for steroid-induced osteoporosis. (Q34542004)

2 August 2017

0 references

1 reference

title

Bisphosphonates for steroid-induced osteoporosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6461188&resulttype=core&format=json

13 May 2020

0 references

Claire S Allen

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6461188&resulttype=core&format=json

13 May 2020

James Hs Yeung

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6461188&resulttype=core&format=json

13 May 2020

Ben Vandermeer

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6461188&resulttype=core&format=json

13 May 2020

Joanne Homik

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6461188&resulttype=core&format=json

13 May 2020

publication date

5 October 2016

1 reference

Cochrane Database of Systematic Reviews

2 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6461188&resulttype=core&format=json

13 May 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6461188&resulttype=core&format=json

13 May 2020

page(s)

CD001347

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6461188&resulttype=core&format=json

Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial

13 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001347.PUB2

Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001347.PUB2

Effects of 4-year treatment with once-weekly clodronate on prevention of corticosteroid-induced bone loss and fractures in patients with arthritis: evaluation with dual-energy X-ray absorptiometry and quantitative ultrasound

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001347.PUB2

Cyclical etidronate increases bone density in the spine and hip of postmenopausal women receiving long term corticosteroid treatment. A double blind, randomised placebo controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001347.PUB2

Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001347.PUB2

Ibandronate increases cortical bone density in patients with systemic lupus erythematosus on long-term glucocorticoid

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001347.PUB2

A double blind placebo controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long-term oral corticosteroid treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001347.PUB2

Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001347.PUB2

Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001347.PUB2

A comparison of calcium, calcitriol, and alendronate in corticosteroid-treated premenopausal patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001347.PUB2

Clinical trial: comparison of alendronate and alfacalcidol in glucocorticoid-associated osteoporosis in patients with ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001347.PUB2

Alendronate protects premenopausal women from bone loss and fracture associated with high-dose glucocorticoid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001347.PUB2

Effect of alendronate on glucocorticoid-induced osteoporosis in Japanese women with systemic autoimmune diseases: versus alfacalcidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001347.PUB2

Risedronate therapy for the prevention of steroid-induced osteoporosis in patients with minimal-change nephrotic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001347.PUB2

Oral pamidronate prevents high-dose glucocorticoid-induced lumbar spine bone loss in premenopausal connective tissue disease (mainly lupus) patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001347.PUB2

Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001347.PUB2

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001347.PUB2

Glucocorticoid-induced osteoporosis: pathophysiology and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001347.PUB2

Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001347.PUB2

Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001347.PUB2

Does treatment with bisphosphonates endanger the human pregnancy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001347.PUB2

Practice patterns in patients at risk for glucocorticoid-induced osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001347.PUB2

Vertebral fracture assessment using a semiquantitative technique.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001347.PUB2

Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis The Study of Osteoporotic Fractures Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001347.PUB2

Studies of the oral bioavailability of alendronate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001347.PUB2

American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001347.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001347.PUB2

Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001347.PUB2

Increased risk for atypical fractures associated with bisphosphonate use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001347.PUB2

A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001347.PUB2

Bisphosphonates in patients with autoimmune rheumatic diseases: Can they be used in women of childbearing age?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001347.PUB2

Prevalence and incidence of vertebral deformities

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001347.PUB2

Safety of bisphosphonates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001347.PUB2

Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001347.PUB2

Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001347.PUB2

The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001347.PUB2

A systematic review identifies a lack of standardization in methods for handling missing variance data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001347.PUB2

Bisphosphonates for steroid induced osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001347.PUB2

A metaanalysis on the use of bisphosphonates in corticosteroid induced osteoporosis

21 January 2018

1 reference

12 December 2020

Evaluation of the efficacy of etidronate therapy in preventing glucocorticoid-induced bone loss in patients with inflammatory rheumatic diseases. A randomized study

1 reference

12 December 2020

The prevention of corticosteroid-induced bone loss with intermittent cyclical etidronate

1 reference

12 December 2020

Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study

1 reference

12 December 2020

Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study

1 reference

12 December 2020

Efficacy of intermittent etidronate therapy for corticosteroid-induced osteoporosis in patients with diffuse connective tissue disease

1 reference

12 December 2020

Influence of cyclic intravenous pamidronate on proinflammatory monocytic cytokine profiles and bone density in rheumatoid arthritis treated with low dose prednisolone and methotrexate

1 reference

12 December 2020

The clinical benefits to bone mineral density were shown by cyclical oral etidronate administration in steroid induced osteoporosis

1 reference

12 December 2020

Glucocorticoid-induced osteoporosis

1 reference

12 December 2020

Etidronate prevents high dose glucocorticoid induced bone loss in premenopausal individuals with systemic autoimmune diseases

1 reference

12 December 2020

Effect of intermittent cyclical etidronate therapy on corticosteroid induced osteoporosis in Japanese patients with connective tissue disease: 3 year followup.

1 reference

12 December 2020

Oral glucocorticoid use is associated with an increased risk of fracture

1 reference

12 December 2020

Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985-1989

1 reference

12 December 2020

Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis

1 reference

12 December 2020

Effect of risedronate on high-dose corticosteroid-induced bone loss in patients with glomerular disease

1 reference

12 December 2020

[Activate vitamin D3 or bisphosphonate in glucocorticoid-induced osteoporosis]

1 reference

12 December 2020

Risedronate, an effective treatment for glucocorticoid-induced bone loss in CKD patients with or without concomitant active vitamin D (PRIUS-CKD)

1 reference

12 December 2020

A double-blind placebo-controlled study of intravenous clodronate for prevention of steroid-induced bone loss in inflammatory bowel disease

1 reference

12 December 2020

Effects of monthly intramuscular neridronate in rheumatic patients in chronic treatment with low-dose glucocorticoids.

1 reference

12 December 2020

Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate

1 reference

12 December 2020

Prevention of glucocorticoid-induced osteoporosis in immunobullous diseases with alendronate: a randomized, double-blind, placebo-controlled study

1 reference

12 December 2020

Quality assurance study of the use of preventative therapies in glucocorticoid-induced osteoporosis in early inflammatory arthritis: results from the CATCH cohort

1 reference

12 December 2020

Once-monthly oral ibandronate provides significant improvement in bone mineral density in postmenopausal women treated with glucocorticoids for inflammatory rheumatic diseases: a 12-month, randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

Incidence of atypical nontraumatic diaphyseal fractures of the femur

1 reference

12 December 2020

[Glucocorticoid-induced osteoporosis]

1 reference

12 December 2020

[Pharmacological treatment of other types of secondary osteoporosis]

1 reference

12 December 2020

A newly developed spine deformity index (SDI) to quantitate vertebral crush fractures in patients with osteoporosis

1 reference

12 December 2020

Mineral loss in cortical and trabecular bone during high-dose prednisone treatment

1 reference

12 December 2020

Assessing vertebral fractures. National Osteoporosis Foundation Working Group on Vertebral Fractures

1 reference

12 December 2020

Cyclical etidronate in the prevention of bone loss in corticosteroid-treated primary biliary cirrhosis. A prospective, controlled pilot study

1 reference

12 December 2020

Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis

1 reference

12 December 2020

Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate: a randomized trial

1 reference

12 December 2020

Cyclical etidronate increases lumbar spine bone density in patients on long-term glucocorticosteroid therapy.

1 reference

12 December 2020

Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. Ciblos Study Group

1 reference

12 December 2020

Clodronate is effective in preventing corticosteroid-induced bone loss among asthmatic patients

1 reference

12 December 2020

Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group

1 reference

12 December 2020

10.1002/14651858.CD001347.PUB2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6461188&resulttype=core&format=json

13 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6461188&resulttype=core&format=json

13 May 2020

1 reference